Recruiting

Phase 1

PACERPersonalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Sponsor:

Stanford University

Code:

NCT06080061

Conditions

Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Hypofractionated accelerated radiation therapy

Study Details

Brief summary:

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Conditions

Lung Cancer

Study ID

NCT06080061

Start date

Oct 25, 2023

Status verified date

Apr, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Nov, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
ECOG performance status of 0-2
Age ≥ 18 years old
Ability to understand and the willingness to personally sign the written IRB approved informed consent document
Estimated life expectancy of 12 weeks or longer

Exclusion Criteria:

Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
Age < 18 years old
Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
Diagnosis of interstitial pulmonary fibrosis
Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Study Design

Enrollment

45 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Hypofractionated accelerated radiation therapy (HART)

Patients will either be treated with 60-66 Gy in 30, 25, or 20 fractions based on ability to meet constraints to key organs at risk

Interventions

Hypofractionated accelerated radiation therapy

Primary outcome measure

Dose limiting pulmonary and esophageal toxicity [ Time Frame: 9 months ]

Central Contacts and Locations

Central contacts

Aastha Dubey

650-725-2084 adubey7@stanford@stanford.edu

Sonya Boyd

650-723-2732 boydso@stanford.edu

Locations

Stanford University

Recruiting

Palo Alto, California, United States, 94305

Contacts

Aastha Dubey

650-725-2084 adubey7@stanford.edu

Sonya Boyd

650-723-2732 boydso@stanford.edu

Principal Investigator:

Joseph A Jaoude, MD

Stanford Cancer Center South Bay

Recruiting

San Jose, California, United States, 95124

Contacts

Aastha Dubey

650-725-2084 adubey7@stanford.edu

Sonya Boyd

650-723-2732 boydso@stanford.edu

Principal Investigator:

Joseph A Jaoude, MD

More Information

Sponsor

Stanford University

Last update posted

Apr 7, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Stanford University on 2026-04-07.